Josep Darbà

1.3k total citations
109 papers, 906 citations indexed

About

Josep Darbà is a scholar working on Economics and Econometrics, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Josep Darbà has authored 109 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Economics and Econometrics, 21 papers in Epidemiology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Josep Darbà's work include Health Systems, Economic Evaluations, Quality of Life (24 papers), Asthma and respiratory diseases (10 papers) and Pharmaceutical Economics and Policy (9 papers). Josep Darbà is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (24 papers), Asthma and respiratory diseases (10 papers) and Pharmaceutical Economics and Policy (9 papers). Josep Darbà collaborates with scholars based in Spain, United Kingdom and United States. Josep Darbà's co-authors include Rainel Sánchez-de la Rosa, Javier Rejas, Mark Sculpher, Loretto Lacey, Christopher Bridle, Antoni Sicras‐Mainar, Joan Rovira, Steven Duffy, Suetonia C. Palmer and R.P. Riemsma and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Josep Darbà

94 papers receiving 867 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Josep Darbà Spain 16 191 160 140 131 129 109 906
Nishan Sengupta United States 15 240 1.3× 108 0.7× 85 0.6× 78 0.6× 56 0.4× 42 1.1k
France Vrijens United States 20 174 0.9× 240 1.5× 211 1.5× 96 0.7× 304 2.4× 78 1.2k
Ghislaine van Mastrigt Netherlands 15 281 1.5× 93 0.6× 89 0.6× 108 0.8× 57 0.4× 46 966
Yong Fang Kuo United States 12 112 0.6× 114 0.7× 133 0.9× 128 1.0× 90 0.7× 26 888
Mona L. Martin United States 15 99 0.5× 105 0.7× 96 0.7× 185 1.4× 93 0.7× 43 1.1k
Frank Verheyen Germany 16 149 0.8× 68 0.4× 73 0.5× 162 1.2× 85 0.7× 53 1.2k
Paulus Kristanto Belgium 9 173 0.9× 251 1.6× 115 0.8× 71 0.5× 73 0.6× 19 1.7k
Arantzazu Arrospide Spain 17 173 0.9× 125 0.8× 80 0.6× 146 1.1× 48 0.4× 66 831
Betina T. Blak United Kingdom 12 77 0.4× 103 0.6× 85 0.6× 215 1.6× 107 0.8× 24 1.1k
James Harnett United States 18 126 0.7× 417 2.6× 85 0.6× 203 1.5× 88 0.7× 59 1.1k

Countries citing papers authored by Josep Darbà

Since Specialization
Citations

This map shows the geographic impact of Josep Darbà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josep Darbà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josep Darbà more than expected).

Fields of papers citing papers by Josep Darbà

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josep Darbà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josep Darbà. The network helps show where Josep Darbà may publish in the future.

Co-authorship network of co-authors of Josep Darbà

This figure shows the co-authorship network connecting the top 25 collaborators of Josep Darbà. A scholar is included among the top collaborators of Josep Darbà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josep Darbà. Josep Darbà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Darbà, Josep, et al.. (2025). Hepatocellular carcinoma: what are the differential costs compared to the general population?. Journal of Medical Economics. 28(1). 471–478. 1 indexed citations
2.
Darbà, Josep, et al.. (2024). Incidence and medical costs of lupus in Spanish hospitals: a retrospective database analysis. Orphanet Journal of Rare Diseases. 19(1). 74–74. 2 indexed citations
3.
Darbà, Josep, et al.. (2024). Gastric cancer in Spain: evaluating productivity loss and economic impact. Journal of Medical Economics. 27(1). 1331–1336. 1 indexed citations
4.
Darbà, Josep, et al.. (2023). Incidence and medical costs of chronic obstructive respiratory disease in Spanish hospitals: a retrospective database analysis. Journal of Medical Economics. 26(1). 335–341. 4 indexed citations
5.
Rejas, Javier, Antoni Sicras‐Mainar, & Josep Darbà. (2021). Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain. Therapeutic Advances in Musculoskeletal Disease. 13. 1759720X211010599–1759720X211010599. 5 indexed citations
6.
7.
Rejas, Javier, et al.. (2020). PDG28 Future Projections of Opioids Utilization and Cost in Patient with Chronic Osteoarthritis PAIN in Spain. Value in Health. 23. S525–S525. 1 indexed citations
8.
Darbà, Josep, et al.. (2020). Results after 10 years of colorectal cancer screenings in Spain: Hospital incidence and in-hospital mortality (2011–2016). PLoS ONE. 15(2). e0228795–e0228795. 7 indexed citations
9.
Darbà, Josep, et al.. (2020). Removal Statement. Current Medical Research and Opinion. 37(1). i–i. 1 indexed citations
10.
Darbà, Josep, et al.. (2019). Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ Open. 9(11). e031271–e031271. 6 indexed citations
11.
12.
Darbà, Josep, et al.. (2019). The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period. BMC Cancer. 19(1). 992–992. 13 indexed citations
13.
Darbà, Josep, et al.. (2015). The Importance of Inhaler Devices: An Incorrect Inhaler Technique Leads to Suboptimal Medication Compliance In Patients With Copd. Value in Health. 18(7). A362–A362. 1 indexed citations
14.
15.
Darbà, Josep, et al.. (2015). Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. ClinicoEconomics and Outcomes Research. 7. 105–105. 16 indexed citations
16.
Darbà, Josep, et al.. (2015). Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain. ClinicoEconomics and Outcomes Research. 7. 387–387. 20 indexed citations
17.
Darbà, Josep, et al.. (2014). Disability adjusted life years lost due to diabetes in france, Italy, Germany, Spain and the United Kingdom: A burden of illness study. Value in Health. 17(3). A262–A262. 1 indexed citations
18.
19.
Darbà, Josep, et al.. (2014). Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine. 32(39). 5006–5012. 12 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nishan Sengupta Breakdown of academic impact, for papers by France Vrijens Breakdown of academic impact, for papers by Ghislaine van Mastrigt Breakdown of academic impact, for papers by Yong Fang Kuo Breakdown of academic impact, for papers by Mona L. Martin Breakdown of academic impact, for papers by Frank Verheyen Breakdown of academic impact, for papers by Paulus Kristanto Breakdown of academic impact, for papers by Arantzazu Arrospide Breakdown of academic impact, for papers by Betina T. Blak Breakdown of academic impact, for papers by James Harnett
Rankless by CCL
2026